HER2-low breast cancer is gaining attention not only because of its potential clinical benefits from novel ADCs but also because of its possibly unique biological characteristics compared with HER2-0 and HER2-positive BCs (A summary of current studies cornering HER2-low BCs in NACT shown in Supplementary Table S6). This evidence concerns the gene ERBB2 and breast carcinoma.